Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05439460 · ClinicalTrials.gov registry record · Phase 4
Management of Acute Pulmonary Hypertensive Crisis in Children With Known Pulmonary Arterial Hypertension
A Phase 4 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT05439460: Completed Phase 4 study, sponsored by Stanford University.
NCT05439460 is a Phase 4 study that has completed, run by Stanford University. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05439460, a Phase 4 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
Pulmonary arterial hypertension (PAH) is a disease where the blood pressure in the pulmonary arteries (PAP) is high. PAH increases the risk of adverse events, including death, during and or after procedures. The severity of baseline PAH correlates with the incidence of major complications, such that those with PAP higher than their systemic blood pressure (SBP) had a 8 fold increased risk of complications. These children present for procedures where an acute exacerbation of their chronic illness-termed Pulmonary Hypertensive (PH)crisis, can occur, often resulting in death if not detected and managed expeditiously. Unfortunately there is little data and no consensus in the pediatric literature on how PH crisis should be managed. \--------------------------------------------------------------------------------
Interventions
- DRUG Epinephrine
- DRUG Phenylephrine
- DRUG Arginine Vasopressin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2012-01 |
| Est. Completion | 2014-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05439460
The ClinicalTrials.gov registry entry for NCT05439460 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Epinephrine is the first listed.
NCT05439460 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05439460 about?
NCT05439460 is a clinical study titled "Management of Acute Pulmonary Hypertensive Crisis in Children With Known Pulmonary Arterial Hypertension". Pulmonary arterial hypertension (PAH) is a disease where the blood pressure in the pulmonary arteries (PAP) is high. PAH increases the risk of adverse events, including death, during and or after procedures. The severity of baseline PAH correlates with the incidence of major complications, such that...
What is the current status of trial NCT05439460?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2012-01. Estimated completion is 2014-06.
What interventions are being tested in trial NCT05439460?
The interventions under investigation include: Epinephrine (DRUG), Phenylephrine (DRUG), Arginine Vasopressin (DRUG).
Who is sponsoring clinical trial NCT05439460?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.